Yongkang Xu
No. 1, Minde Road, Donghu District, P.R. China
Nanchang, China
Nanchang, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
SERPINE2-mediated activation of JAK2/STAT3 facilitates NRF2 nuclear translocation and GCLC transcription to confer ferroptosis resistance and lenvatinib resistance in hepatocellular carcinoma.
Journal: Journal of experimental & clinical cancer research : CR
Published: February 28, 2026
Establishment and Validation of a Novel Nutritional-Immune-Inflammatory Score Model for Predicting Survival Prognosis in Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors.
Journal: Journal of inflammation research
Published: June 11, 2025
Systematic pan-cancer analysis identifies PKNOX1 as a potential prognostic and immunological biomarker and its functional validation.
Journal: Frontiers in immunology
Published: November 24, 2024
USP11 promotes lipogenesis and tumorigenesis by regulating SREBF1 stability in hepatocellular carcinoma.
Journal: Cell communication and signaling : CCS
Published: September 18, 2024
The role of ubiquitination and deubiquitination in cancer lipid metabolism.
Journal: Frontiers in oncology
Published: July 15, 2024
The Value of Chemokine and Chemokine Receptors in Diagnosis, Prognosis, and Immunotherapy of Hepatocellular Carcinoma.
Journal: Cancer management and research
Published: January 12, 2024
Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma.
Journal: Cancer medicine
Published: October 01, 2023
Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study.
Journal: Therapeutics and clinical risk management
Published: June 26, 2023
CKLF as a Prognostic Biomarker and Its Association with Immune Infiltration in Hepatocellular Carcinoma.
Journal: Current oncology (Toronto, Ont.)
Published: November 14, 2022
Efficacy and Safety of Regorafenib with or without PD-1 Inhibitors as Second-Line Therapy for Advanced Hepatocellular Carcinoma in Real-World Clinical Practice.
Journal: OncoTargets and therapy
Published: July 29, 2022
PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib.
Journal: Frontiers in oncology
Published: June 07, 2022
Last Updated: 09/26/2026